1. The use of lactose as a means to stabilize the composition, in particular lyophilized compositions comprising voriconazole and a mixture of beta-hydroxypropyl tsiklodekstrina.2. Use according to claim 1 wherein the stabilizing amount of lactose, based on the lactose monohydrate is at least 3, preferably from 4 to 10 parts by weight relative vorikonazola.3. A method for stabilizing a composition comprising a mixture of voriconazole and hydroxypropyl-beta-cyclodextrin, wherein the method comprises providing a stage- aqueous solution comprising voriconazole and hydroxypropyl-beta-cyclodextrin, preferably in a concentration of at least 10 mg / ml of voriconazole - adding a stabilizing amount of lactose to said aqueous solution and, optionally, - a stabilized lyophilized kompozitsii.4 obtained. Stable composition for intravenous voriconazole, comprising one part by weight of voriconazole, 10-30 parts by weight of 2-hydroxypropyl-beta-cyclodextrin, and at least 3, preferably from 4 to 10 parts by weight lactose, in based on the monohydrate laktozy.5. A composition according to claim 4, combined with an aqueous diluent solution gives a stabilized voriconazole comprising voriconazole in a concentration of 10 mg / ml of hydroxypropyl-beta-cyclodextrin in a concentration of 100-300 mg / ml and lactose at a concentration of at least 30 mg / ml, preferably between 40 and 100 mg / ml (expressed in lactose monohydrate) .6. A composition according to claim 4 or 5, wherein the 2-hydroxypropyl-beta-cyclodextrin is a highly substituted 2-hydroxypropyl-beta-cycle1. Применение лактозы в качестве средства для стабилизации композиции, в частности, лиофилизированной композиции, включающей в себя смесь вориконазола и гидроксипропил-бета-циклодекстрина.2. Применение по п.1, в котором стабилизирующее количество лактозы, в пересчете на моногидрат лактозы составляет, по меньшей мере, 3, предпочтительно, от 4 до 10 массовых частей относительно вориконазола.3. Способ стабилизации композиции,
